Exclusive enteral nutrition for adults with active, complicated Crohn's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, prospective observational cohort in which adults with active Crohn's disease start exclusive enteral nutrition (EEN) at baseline and are followed for 12 weeks. EEN is used as the main induction therapy and details of formula, route, calories, and duration are recorded while other Crohn's medications are generally avoided. The primary endpoint is clinical remission at Week 12, with secondary endpoints including clinical response, endoscopic outcomes when performed, inflammatory marker normalization, and nutritional/BMI changes. Patients with large abscesses may receive percutaneous drainage and antibiotics when clinically indicated as part of routine care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years.
2. Diagnosis of Crohn's disease established on the basis of overall clinical assessment, including compatible clinical history and standard endoscopic, histologic, and/or radiologic findings, as determined by the treating physician. Histologic confirmation at baseline is not required if endoscopy or biopsy is not feasible or clinically inappropriate because of severe disease, poor nutritional status, or intra-abdominal abscess/sepsis.
3. Active Crohn's disease at baseline, as determined by the treating physician.
4. Willingness to initiate and receive exclusive enteral nutrition (EEN) as the sole induction therapy as part of physician-directed routine care.
5. Presence of malnutrition or nutritional risk and clinical indication for EEN.
6. Patients with intestinal complications, including enteric fistula, intestinal stricture, and/or intra-abdominal abscess, are eligible if considered appropriate for EEN-based management by the treating physician.
7. Ability and willingness to provide written informed consent and to comply with study assessments and follow-up for 12 weeks.

Optional clarifying note:

In participants without histologic confirmation at baseline, the diagnosis may be further confirmed during follow-up when clinically feasible, including by endoscopic biopsy or surgical pathology.

Exclusion Criteria

1. Any absolute contraindication to enteral nutrition, including but not limited to gastrointestinal perforation, uncontrolled gastrointestinal bleeding, severe hemodynamic instability/shock, or other conditions where enteral feeding is not clinically appropriate.
2. Immediate need for emergency surgery at baseline.
3. Inability or unwillingness to receive EEN as the sole induction therapy at baseline.
4. Any condition that, in the investigator's opinion, would make participation unsafe or would substantially interfere with study assessments or follow-up.

Where it's running

• The Sixth Affiliated Hospital, Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Wei Wang, MD
• Email: wangw239@mail.sysu.edu.cn
• Phone: 86-18702046420

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Iron treatment for children and young adults with Crohn’s disease and iron deficiency anemia

  This study tests how different iron treatment approaches work for kids and young adults with Crohn’s disease and iron deficiency anemia.

  Recruiting Phase 4 Weill Medical College of Cornell University · New York, New York · NCT07925450

• Autologous intestinal organoids applied to Crohn's ulcers in a first-in-human dose-escalation study

  This early-phase study tests a patient-derived intestinal organoid therapy (ATORM-C) delivered during colonoscopy to Crohn’s ulcers to see if it is safe and tolerable and to get a sense of healing.

  Recruiting Phase 1 Organoidsciences LTD. · Seoul · NCT07822087

• SL-325 in Crohn's Disease: a phase 2 test for adults with moderate to severe disease

  This phase 2 study tests SL-325 against placebo in adults with moderately to severely active Crohn's disease to see if it helps improve symptoms and disease activity.

  Recruiting Phase 2 Shattuck Labs, Inc. · Little Rock, Arkansas and 19 other locations · NCT07753850

• Advanced therapies for moderately to severely active Crohn's disease or ulcerative colitis in adults

  This study tests combinations of risankizumab with either trosunilimab or ABBV-701 in adults with moderately to severely active Crohn's disease or ulcerative colitis.

  Recruiting at 66 sites Phase 2 AbbVie · Dothan, Alabama and 65 other locations · NCT07697456

• Stop PPI in active IBD: can you safely go without acid-suppressing meds?

  This study tests whether people with inflammatory bowel disease who have been on proton pump inhibitors can stop taking them and still manage their symptoms.

  Recruiting Phase 4 University of Nottingham · Nottingham · NCT07691138

• Tabellvi for moderate to severe Crohn's disease in Chinese adults

  This real-world, single-arm study tests Tabellvi® (adalimumab) in Chinese adults with moderate to severe Crohn's disease to see how often side effects occur and whether many patients reach remission by week 26.

  Recruiting Phase 4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Fuyang, Anhui and 6 other locations · NCT07663526

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.